ERBB2 and neoplasm: Germline BRCA1/2 mutation carriers and non‐carriers had similar ages of onset, tumor sizes, lymph node statuses, and hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status in the CHCAMS cohort (all p > 0.05; Figure S2, Supporting Information).